Our mission is to make healthcare more affordable and to improve access to important medicines through the provision of high-quality small-molecule generics and hybrids to patients all around the world. Currently our products are approved by regulatory agencies in around 100 countries and marketed through strategic partnerships and - in dedicated areas - through direct sales.
Complex small-molecule generics and hybrids form the backbone of our product portfolio. Our generics product range covers many therapeutic areas with medicines to treat a large number of diverse indications. One common factor drives our business and that is the pursuit of innovative excellence with a clear preference for complex synthesis and sophisticated dosage forms. This results in first-rate medicines that meet market needs, supported by strong patents that guarantee a long product lifespan. Our products are marketed at the earliest possible opportunity and sold at competitive prices.
Synthon’s strategy from its inception included the development of a vertically integrated organization for small-molecule generics, controlling every facet of the development chain beginning with research, development and production of active pharmaceutical ingredients through to manufacture and sale of our drug products. Our pipeline is well-filled with research projects and pending regulatory applications.
Generic medicines (or: generics) are fully equivalent to the originator product in strength, route of administration, quality and performance characteristics, and intended use.
In 2016, Synthon successfully concluded the decentralized procedures for glatiramer acetate 20 mg/mL, a therapeutically equivalent version of the originator medicine Copaxone® for the treatment of relapsing remitting multiple sclerosis (RRMS) in Europe.
If you experience any side effects associated with a Synthon product, we need to get in touch with you for further information. Please contact us to report an adverse event related to Synthon products by sending us an e-mail.